4516.T
Nippon Shinyaku Co.,Ltd.
プライム · 医薬品 · 医薬品 · JP
JPY 3,499.00
+0.06%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 166.0B | 170.8B | 160.2B | 148.3B | 144.2B |
| Cost of Revenue | 12.7B | 57.5B | 51.1B | 50.2B | 56.0B |
| Gross Profit | 26.9B | 113.3B | 109.1B | 98.0B | 88.2B |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 10.0B | 43.6B | 38.0B | 35.0B | 34.8B |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 794.0M | 560.0M | 2.2B | 1.3B | 1.1B |
| Total Operating Expenses | 10.8B | 44.1B | 40.2B | 36.2B | 35.9B |
| Cost and Expenses | 131.0B | 135.3B | 124.8B | 115.0B | 114.1B |
| Operating Income (EBIT) | 35.0B | 35.5B | 35.5B | 33.3B | 30.0B |
| Non-Operating | |||||
| Interest Income | 468.0M | 1.1B | 830.0M | 650.0M | 575.0M |
| Interest Expense | 46.0M | 166.0M | 145.0M | 329.0M | 136.0M |
| Net Interest Income | 422.0M | 966.0M | 685.0M | 321.0M | 439.0M |
| Other Non-Op Income/Expense | 169.0M | 3.0B | 874.0M | 3.2B | 1.9B |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 10.5B | 36.5B | 36.1B | 33.6B | 30.5B |
| Income Tax Expense | 2.2B | 6.7B | 3.6B | 7.8B | 7.7B |
| Bottom Line | |||||
| Net Income | 29.9B | 29.7B | 32.6B | 25.9B | 22.8B |
| Earnings from Cont. Ops | — | — | — | — | — |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 29.9B | 29.7B | 32.6B | 25.9B | 22.8B |
| Per Share | |||||
| Basic EPS | ¥443 | ¥441 | ¥483 | ¥384 | ¥339 |
| Diluted EPS | ¥443 | ¥441 | ¥483 | — | — |
| Revenue Per Share | ¥2,465 | ¥2,535 | ¥2,379 | ¥2,201 | ¥2,141 |
| Shares | |||||
| Basic Shares Outstanding | 67.4M | 67.4M | 67.4M | 67.4M | 67.4M |
| Diluted Shares Outstanding | — | — | — | — | — |
| Profitability Metrics | |||||
| EBITDA | 11.7B | 42.1B | 41.5B | 38.3B | 35.1B |
| D&A | 1.6B | 6.6B | 6.0B | 5.0B | 5.0B |
| EBIT | 35.0B | 35.5B | 35.5B | 33.3B | 30.0B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026